You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

November 28, 2017

Indonesia Implementing Halal Assurance System

Subscribe to Updates
Informed Counsel

The private sector in Indonesia has been vocal about their concern for the government’s plan to make halal certification mandatory, believing that this requirement will add a greater burden to their business. Amid criticism, the government is moving forward with its halal assurance system, citing, among other reasons, the need for a government agency to be the new halal certification authority to create greater transparency in the existing certification process.

Halal Regulators

Halal certificates can currently be obtained from the Islamic Council (MUI), which is an autonomous organization not belonging to the government. With the introduction of the new Indonesian halal assurance system earlier this year, the Halal Product Assurance Organizing Agency (BPJPH) was inaugurated by the Ministry of Religious Affairs on October 11, 2017, to take over the MUI’s main halal certification duties and is expected to start operations by 2018.

The BPJPH has the authority to issue and revoke the halal certificate and halal label on products, carry out administration of halal certification of domestic and foreign products, supervise the guarantee of halal products, work with halal inspection agencies (LPH) on product inspection and/or testing, and conduct public relations campaigns to inform the public about halal products.

Once the BPJPH commences operations, the MUI will continue to play a role in the halal certification process by providing religious decrees to determine the halal status of a product. MUI decrees must be submitted to the BPJPH as the basis for the issuance of a halal certificate. Additionally, the MUI will work with the BPJPH in certification of halal auditors and accreditation of LPHs.

Transitional Period

Two draft halal regulations—one covering governmental fees and the other covering implementation and guidelines of the halal assurance system—have been prepared and are being reviewed by the Ministry of Finance and the Ministry of Laws and Human Rights. Until the two laws enter into force, halal certificates will be issued by the MUI. After the laws take effect, halal certificates that have been issued by the MUI will remain valid until the date indicated on the certificate, with the next renewal of such certificates to be filed with the BPJPH.

Currently, each halal certificate that has been issued by the MUI is valid for two years. Later, upon the transfer to the BPJPH, the validity period of each certificate will be four years with the possibility of renewal.

The Indonesian government has imposed a deadline of October 17, 2019, for all required products to be halal-certified. However, there is a grace period of three years for food and beverage products, and a grace period of five years for cosmetics and drugs. It is important to note that life-saving medicines which have no substitutes are likely to be exempted from the halal-certificate obligation.

Products That Require Halal Certification

Although an exhaustive list is not yet available, the types of products that generally must be halal-certified include food, beverages, medicinal products, cosmetics, chemical products, biological products, and genetically engineered products.

To obtain halal status, both product materials and manufacturing processes will be inspected. Each company must have an in-house supervisor set up a halal assurance system and conduct periodic inspections to maintain the system. Products that contain non-halal substances or are non-halal because of their manufacturing process can still be sold in Indonesia but must be labeled “non-halal.”

Imported Products

Indonesia’s National Agency of Drug and Food Control (BPOM) currently requires products that will be imported, distributed, and traded in Indonesia to have an MUI halal certificate if the applicant wishes to include halal information/logo on their product label. In the future, this requirement will not be necessary if the product has been certified by the halal certification agency in its country of origin.

The BPJPH, the Ministry of Religious Affairs, and the Ministry of Foreign Affairs are collaborating on drafting an intergovernmental cooperation agreement for Indonesia and other nations. This bilateral agreement will enable certificates issued by a halal certification agency in one country to be recognized in Indonesia, and, once in effect, applicants will only be required to register their halal logo with the BPJPH with no additional certification actions needed.

Indonesia’s new halal assurance system may appear complicated. However, the government is expending considerable effort in simplifying procedures and requirements, and setting costs that are affordable for all. With the establishment of the BPJPH and the drafting of halal assurance laws, it is anticipated that the halal assurance system in Indonesia will soon be more efficient than ever before.

Download Full Article
Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

June 24, 2026
Patent enablement requirements are provided under Article 102 of Vietnam’s Law on Intellectual Property (IP Law). In particular, a patent specification must “fully and clearly disclose the nature of the invention to such an extent that, based on the specification, a person having ordinary skill in the relevant art can implement the invention.” In pharmaceutical and biotechnology patents, this requirement is more complicated and subject to more rigorous assessment. The Patent Examination Guidelines (Guidelines) of the Intellectual Property Office of Vietnam (IP Office) were amended in March 2026 to introduce Annexes III and IV for the pharmaceutical and biotechnology sectors, in which Annex III provides detailed guidelines on the assessment of specification requirements. These amendments were made under a project for strengthening capacity in industrial property examination between the Japan International Cooperation Agency (JICA) and the IP Office. Annex III provides detailed instructions on how examiners assess enablement in a pharmaceutical or biotechnology application, and offers examples of acceptable and unacceptable descriptions with regard to the enablement aspect. Enablement Requirements in Pharma and Biotech Patents Article 12.7 of Circular 10/2026/TT-BKHCN (Circular 10) adds to the requirements of Article 102 of the IP Law that the description must demonstrate the novelty, inventive step, and industrial applicability of the technical solution. For pharmaceutical composition subject matters, Article 12.9 of Circular 10 sets out that the description must present the results of clinical trials and/or the pharmacological effects of the claimed pharmaceutical composition, and must include at least the following information: Substance/mixture used. Testing method (system) employed. Information on the test results. Correlation between the pharmacological effects obtained from the tests and the application of the pharmaceutical product in the prevention, diagnosis, and treatment of diseases. The Guidelines note that pharmacological study results should be presented in a quantified manner, and pharmacological
Read More
June 19, 2026
For the first time, Thailand’s Food and Drug Administration (FDA) has published a consolidated list identifying all substances that have successfully passed its novel food safety evaluation process. The list is a step forward in regulatory transparency, but it also highlights a feature of the Thai regime that food companies often overlook: each approval is tied exclusively to the company that applied for it. A substance’s appearance on the list does not give other companies the green light to use it. This article examines the structure of Thailand’s novel food approval framework, the implications of applicant exclusivity, and the strategic choices it requires of food companies looking to bring novel ingredients to the Thai market. Thai FDA Food Safety Evaluation Framework Notification No. 376 of the Ministry of Public Health requires novel food substances to undergo a food safety assessment, with an exemption only for novel foods manufactured exclusively for export. The framework also encompasses “foods that do not qualify as novel foods” but which present characteristics warranting a safety evaluation, such as differing quality standards, increased serving sizes, or applications in specific food categories, where such changes affect consumption levels, nutritional value, or consumer safety. The recently published list of foods that passed the safety evaluation by the Thai FDA is structured by substance category and identifies the approved company (domestic manufacturer or importer), country of origin, substance name and trade name, approved purpose of use, and date of the Thai FDA’s approval notification certificate. A notable feature of Thailand’s novel food regime is that the approval result is tied exclusively to the company that submitted the application. Publication of the consolidated list does not constitute a general authorization to use the approved substances. The Thai FDA’s approval certificate specifies the approved conditions of use and the requirements
Read More
June 17, 2026
Thailand’s new labeling requirements for medical devices, which include for the first time a unique device identification (UDI) requirement for software as a medical device (SaMD), take effect on June 20, 2026. The Notification of the Ministry of Public Health regarding Criteria, Methods, and Conditions on Labeling and Instructions for Use for Medical Devices 2025, which replaces a similar notification from 2020, was published in the Government Gazette on December 22, 2025. To ensure clarity, modernity, and patient safety, the regulation requires domestic manufacturers and importers to provide labels and instructions for use (IFU) that are clearly legible, complete, and free of false or misleading claims. It also permits IFU to be provided in electronic format, such as via QR codes, websites, or other digital channels—directly relevant to SaMD, where physical labels are impractical and electronic presentation is the natural medium. The notification distinguishes two categories for labeling language. Home-use medical devices (for lay users outside healthcare facilities) must have labels and IFU in Thai. Professional-use medical devices may display labels and documentation in either Thai or English. This distinction is significant for SaMD developers: software intended for clinical professionals may use English-language interfaces and IFU, while consumer-facing health applications must provide Thai-language content. Labeling and UDI Requirements Labels and IFU must include, at a minimum: Product name and intended purpose Quantity or volume Name and address of domestic manufacturer or importer Thai FDA approval number Lot, version, or serial number Manufacturing date and expiry date For SaMD, the version number requirement is particularly relevant. The regulation also mandates display of a UDI code for SaMD in risk category 2 (moderate-risk), category 3 (moderate- to high-risk), and category 4 (high-risk), according to Thailand’s medical device risk classification system (which complies with the ASEAN Medical Device Directive and the EU
Read More
June 5, 2026
On May 25, 2026, Vietnam’s Ministry of Health issued Circular No. 16/2026/TT-BYT governing free-of-charge medicine support programs for medical establishments (Circular 16). Circular 16 will take effect on July 10, 2026, replacing Circular No. 31/2018/TT-BYT, which currently regulates the same subject matter. Circular 16 introduces several significant changes compared to the existing legal framework. Removal of Prior Approval Requirement Under the current regulations, free-of-charge medicine support programs are divided into two categories: (1) entirely free-of-charge provision of medicines for all types of drugs and (2) partially free-of-charge provision applicable only to brand-name drugs under patent protection or drugs whose generic products with identical active ingredients and dosage forms are available in Vietnam. Under the current regulations, partially free-of-charge programs are subject to mandatory registration with the competent authority, while entirely free-of-charge programs could be implemented without prior approval. A key reform under Circular 16 is that it stipulates only entirely free-of-charge medicine support programs applicable to all types of medicines, thereby eliminating the partially free-of-charge category. In addition, free-of-charge medicine support programs may be carried out solely based on a written agreement between the pharmaceutical company and the medical establishment, without any requirement for prior approval from competent authorities prior to implementation. Written Agreement Requirements Circular 16 requires the pharmaceutical company and medical establishment to enter into a written agreement in accordance with a prescribed template. This agreement must include the following compulsory information: Information on the supported medicines Form of support (entirely free-of-charge provision to patients) Quantity of medicines provided Target patient groups and applicable indications Duration of the program Rights and obligations of each party Transitional provisions on the protection of patients’ rights upon completion of the program The agreement may contain other contents as agreed by the parties, provided that these do not contradict applicable laws.
Read More